Neuroacanthocytosis

Neuroacanthocytosis

No Results

No Results

processing….

Neuroacanthocytosis encompasses a group of genetically heterogenous disorders characterized by neurologic signs and symptoms associated with acanthocytosis, an abnormality of red blood cells. [1, 2, 3] Neurologic problems usually consist of either movement disorders or ataxia, personality changes, cognitive deterioration, [4, 5] axonal neuropathy, and seizures [6] . At some point during the course of the disease, most patients manifest acanthocytosis on the peripheral blood smear, ie, a certain percentage of the patients’ erythrocytes (typically 10-30%) have an unusual starlike appearance with spiky- or thorny-appearing projections. [7]

There has been, and there continues to be, considerable disagreement about which specific diseases should be included under the general term neuroacanthocytosis. This is the understandable result of gradually accumulating knowledge of the molecular and biological bases of these disorders.

The first form of neuroacanthocytosis to be well described in the medical literature is Bassen-Kornzweig disease, or abetalipoproteinemia (1950), [1] which is an autosomal recessive abnormality of lipoprotein metabolism resulting in ataxia combined with acanthocytosis. In the early descriptions, Bassen-Kornzweig disease was compared with a better known condition, Friedreich ataxia. The two are rather similar except that patients with Bassen-Kornzweig disease have acanthocytosis. In fact, the term acanthocyte was originated by the authors of the seminal Bassen-Kornsweig paper.

The second type of neuroacanthocytosis was described in 1960 by Levine [8, 9] and later in 1968 by Critchley [10] . Just as Bassen-Kornsweig disease looks much like Friedreich ataxia, the Levine-Critchley syndrome, as it came to be called, resembles Huntington disease (HD) with prominent choreiform or choreoathetoid movements, progressive dementia, and, in the original descriptions, autosomal dominant inheritance.

One notable difference from HD is that Levine-Critchley syndrome manifests acanthocytosis. When it was originally described, it was also frequently compared with Bassen-Kornzweig disease in that both combined neurologic abnormalities with acanthocytosis, but the Levine-Critchley syndrome had normal lipoproteins as well as a later age of onset. What today is recognized as the Levine-Critchley syndrome is caused by a mutation in a specific gene called chorein (also called VPS13A). Interestingly, it is not clear that the original cases reported by Levine and Critchley had that mutation.

Most genetic diseases for which the term neuroacanthocytosis is appropriate exhibit phenotypes similar to either Bassen-Kornsweig disease or Levine-Critchley syndrome:

Bassen-Kornsweig disease or similar disorders, ie, hereditary lipoprotein disorders that cause a predominantly sensory ataxia involving the dorsal root ganglia and the ensuing spinocerebellar pathways and projections combined with acanthocytosis:

Bassen-Kornsweig disease (abetalipoproteinemia) [11, 12, 13, 14]

Familial hypobetalipoproteinemia

Other lipoprotein disorders of uncertain significance

Similar to Levine-Critchley syndrome, ie, a movement disorder with choreiform or Parkinsonlike features combined with dementia, various other neurologic abnormalities, and acanthocytosis:

Chorea-acanthocytosis (ChAc) [15]

McLeod syndrome (MLS) [16]

Huntington disease–like2 (HDL2) [17, 18]

Pantothenate kinase–associated neurodegeneration (PKAN) [19]

A number of individual cases and families have been reported that do not seem to fit the existing genetic patterns and which may represent new genetic syndromes yet to be elucidated or perhaps are sporadic diseases. [20, 21]

As in many other diseases, there is considerable clinical heterogeneity in these syndromes, which may be caused by environmental interactions as well as the background of other genes and other diseases in the patient. [22]

Finally, a number of systemic diseases (usually sporadic) exist in which the combination of neurologic findings and acanthocytosis may actually be incidental. Examples of this type of neuroacanthocytosis include case reports of patients with hepatic encephalopathy, myxedema, or certain types of vasculitis who at some point in their disease show choreiform features plus acanthocytosis. It is not known why such diseases show these features as an occasional manifestation and, in the authors’ opinion, it is not correct to call these diseases forms of neuroacanthocytosis per se. However, for the sake of completeness, diseases that have been known to occasionally exhibit features of neuroacanthocytosis are listed.

Multisystem pathology is evident, including severe atrophy of the caudate and putamen with loss of small- and medium-sized neurons and an associated astrocytic reaction. Less severe changes are seen in the pallidum.

Neuronal loss and mild gliosis can be seen in the thalamus, substantia nigra, and anterior horn of the spinal cord.

Acanthocytes are seen in peripheral blood smears. Creatine phosphokinase (CPK) level, and occasionally serum transaminases level, are elevated.

Serum vitamin E and lipoprotein levels typically are normal in the neuroacanthocytoses that do not involve abetalipoproteinemia or hypobetalipoproteinemia.

In the few cases for which neurochemical data are available, dopamine was decreased in almost the entire brain, norepinephrine levels were elevated in the putamen and globus pallidus, substance P levels were decreased in the striatum and substantia nigra, and serotonin levels were decreased in the caudate nucleus and substantia nigra. These findings are difficult to interpret because of severe caudate atrophy, concurrent medications, and small sample sizes. [23]

United States

Neuroacanthocytosis is a rare disease for which insufficient epidemiological data are available to draw conclusions about frequency.

Reported causes of death include the following:

Emaciation due to progressive weakness and dysphagia

Tracheobronchial aspiration

Suicide

Neuroacanthocytosis has been reported in several races, but epidemiological data are insufficient to report prevalences.

Data are insufficient, but the condition may be more common in males than in females.

Mean age of onset is 32 years (range, 8-62 y).

Bassen FA, Kornzweig AL. Malformation of the erythrocytes in a case of atypical retinitis pigmentosa. Blood. 1950 Apr. 5(4):381-87. [Medline].

De Franceschi L, Bosman GJ, Mohandas N. Abnormal red cell features associated with hereditary neurodegenerative disorders: the neuroacanthocytosis syndromes. Curr Opin Hematol. 2014 May. 21(3):201-9. [Medline].

Siegl C, Hamminger P, Jank H, Ahting U, Bader B, Danek A, et al. Alterations of red cell membrane properties in neuroacanthocytosis. PLoS One. 2013. 8(10):e76715. [Medline]. [Full Text].

Kartsounis LD, Hardie RJ. The pattern of cognitive impairments in neuroacanthocytosis. A frontosubcortical dementia. Arch Neurol. 1996 Jan. 53(1):77-80. [Medline].

Medalia A, Merriam A, Sandberg M. Neuropsychological deficits in choreoacanthocytosis. Arch Neurol. 1989 May. 46(5):573-5. [Medline].

Tiftikcioglu BI, Dericioglu N, Saygi S. Focal seizures originating from the left temporal lobe in a case with chorea-acanthocytosis. Clin EEG Neurosci. 2006 Jan. 37(1):46-9. [Medline].

Rampoldi L, Danek A, Monaco AP. Clinical features and molecular bases of neuroacanthocytosis. J Mol Med. 2002 Aug. 80(8):475-91. [Medline].

Levine IM, Estes JW, Looney JM. Hereditary neurological disease with acanthocytosis. A new syndrome. Arch Neurol. 1968 Oct. 19(4):403-9. [Medline].

Estes JW, Morley TJ, Levine IM, Emerson CP. A new hereditary acanthocytosis syndrome. Am J Med. 1967 Jun. 42(6):868-81. [Medline].

Critchley EM, Clark DB, Wikler A. Acanthocytosis and neurological disorder without betalipoproteinemia. Arch Neurol. 1968 Feb. 18(2):134-40. [Medline].

Schwartz JF, Rowland LP, Eder H et al. Bassen-Kornzweig syndrome: deficiency of serum beta-lipoprotein. Arch. Neurol. 1963. 8:438-454.

Sharp D, Blinderman L, Combs KA, Kienzle B, Ricci B, Wager-Smith K, et al. Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature. 1993 Sep 2. 365(6441):65-9. [Medline].

Shoulders CC, Brett DJ, Bayliss JD, Narcisi TM, Jarmuz A, Grantham TT, et al. Abetalipoproteinemia is caused by defects of the gene encoding the 97 kDa subunit of a microsomal triglyceride transfer protein. Hum Mol Genet. 1993 Dec. 2(12):2109-16. [Medline].

Talmud PJ, Lloyd JK, Muller DP, Collins DR, Scott J, Humphries S. Genetic evidence from two families that the apolipoprotein B gene is not involved in abetalipoproteinemia. J Clin Invest. 1988 Nov. 82(5):1803-6. [Medline].

Rampoldi L, Dobson-Stone C, Rubio JP, Danek A, Chalmers RM, Wood NW, et al. A conserved sorting-associated protein is mutant in chorea-acanthocytosis. Nat Genet. 2001 Jun. 28(2):119-20. [Medline].

Walker RH, Jung HH, Tison F, Lee S, Danek A. Phenotypic variation among brothers with the McLeod neuroacanthocytosis syndrome. Movem Disord. 2007. 22(pt 2):244-8.

Holmes SE, O’Hearn E, Rosenblatt A, Callahan C, Hwang HS, Ingersoll-Ashworth RG, et al. A repeat expansion in the gene encoding junctophilin-3 is associated with Huntington disease-like 2. Nat Genet. 2001 Dec. 29(4):377-8. [Medline].

Margolis RL, O’Hearn E, Rosenblatt A. A disorder similar to Huntington’s disease is associated with a novel CAG repeat expansion. Ann Neurol. 2001 Dec. 50(6):373-80. [Medline].

Hayflick SJ, Westaway SK, Levinson B, Zhou B, Johnson MA, Ching KH, et al. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med. 2003 Jan 2. 348(1):33-40. [Medline].

Spitz MC, Jankovic J, Killian JM. Familial tic disorder, parkinsonism, motor neuron disease, and acanthocytosis: a new syndrome. Neurology. 1985 Mar. 35(3):366-70. [Medline].

Walker RH, Danek A, Dobson-Stone C, Guerrini R, Jung HH, Lafontaine AL, et al. Developments in neuroacanthocytosis: expanding the spectrum of choreatic syndromes. Mov Disord. 2006 Nov. 21(11):1794-805. [Medline].

Lossos A, Dobson-Stone C, Monaco AP. Early clinical heterogeneity in choreoacanthocytosis. Arch Neurol. 2005 Apr. 62(4):611-4. [Medline].

de Yebenes JG, Brin MF, Mena MA, et al. Neurochemical findings in neuroacanthocytosis. Mov Disord. 1988. 3(4):300-12. [Medline].

Balhara YP, Varghese ST, Kayal M. Neuroacanthocytosis: presenting with depression. J Neuropsychiatry Clin Neurosci. 2006 Summer. 18(3):426. [Medline].

Danek A, Bader B, Walker RH. Antisocial behaviour and neuroacanthocytosis. Int J Clin Pract. 2007 Aug. 61(8):1419; author reply 1419. [Medline].

Gooneratne IK, Weeratunga PN, Gamage R. Teaching video neuroimages: orofacial dyskinesia and oral ulceration due to involuntary biting in neuroacanthocytosis. Neurology. 2014 Feb 25. 82(8):e70. [Medline].

Aggerbeck LP, McMahon JP, Scanu AM. Hypobetalipoproteinemia: clinical and biochemical description of a new kindred with ‘Friedreich’s atazia’. Neurology. 1974 Nov. 24(11):1051-63. [Medline].

Araki W, Hirose S, Mimori Y, Nakamura S, Kimura J, Ohno K, et al. Familial hypobetalipoproteinaemia complicated by cerebellar ataxia and steatocystoma multiplex. J Intern Med. 1991 Feb. 229(2):197-9. [Medline].

Bednarska-Makaruk M, Bisko M, Pulawska MF, Hoffman-Zacharska D, Rodo M, Roszczynko M, et al. Familial defective apolipoprotein B-100 in a group of hypercholesterolaemic patients in Poland. Identification of a new mutation Thr3492Ile in the apolipoprotein B gene. Eur J Hum Genet. 2001 Nov. 9(11):836-42. [Medline].

Linton MF, Farese RV Jr, Young SG. Familial hypobetalipoproteinemia. J Lipid Res. 1993 Apr. 34(4):521-41. [Medline].

Boren J, Ekstrom U, Agren B, Nilsson-Ehle P, Innerarity TL. The molecular mechanism for the genetic disorder familial defective apolipoprotein B100. J Biol Chem. 2001 Mar 23. 276(12):9214-8. [Medline].

Pulai JI, Neuman RJ, Groenewegen AW, Wu J, Schonfeld G. Genetic heterogeneity in familial hypobetalipoproteinemia: linkage and non-linkage to the apoB gene in Caucasian families. Am J Med Genet. 1998 Feb 26. 76(1):79-86. [Medline].

Yuan B, Neuman R, Duan SH, Weber JL, Kwok PY, Saccone NL, et al. Linkage of a gene for familial hypobetalipoproteinemia to chromosome 3p21.1-22. Am J Hum Genet. 2000 May. 66(5):1699-704. [Medline].

Mukoyama M, Kazui H, Sunohara N, Yoshida M, Nonaka I, Satoyoshi E. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes with acanthocytosis: a clinicopathological study of a unique case. J Neurol. 1986 Aug. 233(4):228-32. [Medline].

Prof. Alexander Storch, MD, Dept. of Neurology,. Familial Acanthocytosis with Paroxysmal Exertion-induced Dyskinesias and epilepsy (FAPED). Dresden: Technical University of Dresden; [Full Text].

Charcosset M, Sassolas A, Peretti N, Roy CC, Deslandres C, Sinnett D, et al. Anderson or chylomicron retention disease: molecular impact of five mutations in the SAR1B gene on the structure and the functionality of Sar1b protein. Mol Genet Metab. 2008 Jan. 93(1):74-84. [Medline].

Al-Shali K, Hegele RA. Acanthocytes and disorders of lipoprotein. Danek A, ed. Neuroacanthocytosis syndromes. Dordrecht: Springer; 2004. 21-30.

Danek A, Jung HH, Melone MA, Rampoldi L, Broccoli V, Walker RH. Neuroacanthocytosis: new developments in a neglected group of dementing disorders. J Neurol Sci. 2005 Mar 15. 229-230:171-86. [Medline].

Eto Y, Kitagawa T. Wolman’s disease with hypolipoproteinemia and acanthocytosis: clinical and biochemical observations. J Pediatr. 1970 Nov. 77(5):862-7. [Medline].

Bohlega S, Riley W, Powe J. Neuroacanthocytosis and aprebetalipoproteinemia. Neurology. 1998. 50 (6):1912-1914. [Medline].

Brooks DJ, Ibanez V, Playford ED, et al. Presynaptic and postsynaptic striatal dopaminergic function in neuroacanthocytosis: a positron emission tomographic study. Ann Neurol. 1991 Aug. 30(2):166-71. [Medline].

Dubinsky RM, Hallett M, Levey R, Di Chiro G. Regional brain glucose metabolism in neuroacanthocytosis. Neurology. 1989 Sep. 39(9):1253-5. [Medline].

Tschopp L, Raina G, Salazar Z, Micheli F. Neuroacanthocytosis and carbamazepine responsive paroxysmal dyskinesias. Parkinsonism Relat Disord. 2008. 14(5):440-2. [Medline].

Guehl D, Cuny E, Tison F, Benazzouz A, Bardinet E, Sibon Y. Deep brain pallidal stimulation for movement disorders in neuroacanthocytosis. Neurology. 2007 Jan 9. 68(2):160-1. [Medline].

Wihl G, Volkmann J, Allert N, Lehrke R, Sturm V, Freund HJ. Deep brain stimulation of the internal pallidum did not improve chorea in a patient with neuro-acanthocytosis. Mov Disord. 2001 May. 16(3):572-5. [Medline].

Mclntosh J. Speech/Occupational therapy for neuroacanthocytosis. Movem Disord. 2006. 20:1682.

Lin FC, Wei LJ, Shih PY. Effect of levetiracetam on truncal tic in neuroacanthocytosis. Acta Neurol Taiwan. 2006 Mar. 15(1):38-42. [Medline].

Jones B, Jones EL, Bonney SA, Patel HN, Mensenkamp AR, Eichenbaum-Voline S, et al. Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders. Nat Genet. 2003 May. 34(1):29-31. [Medline].

OMIM#

Name

Mode

Gene, Locus, and Protein

Onset age

Description

Pathology

#200150

ChAc or Levine-Critchley syndrome [8, 9, 10, 15]

Autosomal recessive

VPS13A 9q21

chorein [15]

Adult onset; early to middle age (20-50 y)

Features include choreoathetosis, dystonia, parkinsonism, orofacial dyskinesias, seizures, and neuropathy. Whether the original index cases (ie, Levine, 1960 and 1968; Critchley, 1967 and 1970) were part of the Levine-Critchley syndrome as understood genetically today remain unknown. [8, 9, 10]

Atrophy of the caudate, putamen, globus pallidus, and substantia nigra

+314850

MacLeod Syndrome or MLS [16]

X-linked

Kell blood group gene, XK

Xp21 locus

XK protein

Adult onset middle to late age (40-70 y)

Features include choreoathetosis, dystonia, parkinsonism, seizures, neuropathy, myopathy, and cardiomyopathy.

Atrophy of the caudate, putamen, and globus pallidus; substantia nigra not involved

#606438

Huntington’s Disease-Like 2, HDL2 [17, 18]

Autosomal dominant

(CAG repeat expansion)

JPH3

16q24.3

Junctophilin-3

Onset earlier as repeat size increases (usually 30-40 y)

Features include choreoathetosis, dystonia, parkinsonism, hyperreflexia, dementia, and weight loss.

Atrophy of the caudate and putamen

#234200

PKAN or PANK2 deficiency (previously termed Hallervorden-Spatz disease) [19]

Autosomal recessive

PANK2; 20p13

Childhood onset (by 4-6 y); adult onset subtypes exist

Features include choreoathetosis, dystonia, dysarthria, rigidity, spasticity, and dementia. PKAN also includes the HARP (hypoprebeta-lipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration) subtype.

Iron deposition in the globus pallidus (causes “eye-of-the-tiger” sign on MRIs

#200100

Abeta-lipoprotein-emia [11, 12, 13, 14]

Autosomal recessive

MTP; 4q22- q24

Infancy / childhood

Features include ataxia (sensory ataxia with some cerebellar features), visual loss, mental retardation / dementia, low vitamin E level, high cholesterol level, and abnormal lipoprotein electrophoresis.

Dorsal root ganglia, ascending sensory tracts, cuneate and gracile nuclei of cord, spinocere-bellar projections; possibly some direct cerebellar involvement; retinitis pigmentosa

+107730

FHBL1 [27, 28, 29, 30, 31]

Autosomal recessive

APOB; 2p24

Infancy / childhood

Features include ataxia (sensory ataxia with some cerebellar features), visual loss, and mental retardation / dementia.

Dorsal root ganglia, ascending sensory tracts, cuneate and gracile nuclei of cord, spinocere-bellar projections; possibly some direct cerebellar involvement; retinitis pigmentosa.

%605019

FHBL2 [32, 33]

Possibly autosomal recessive

3p22-p21.2 for some, for others linkage not known

Infancy / childhood

Features are same as for FHBL1.

Same as FHBL1

OMIM

Name

Mode

Locus

Description

#540000

Mitochondrial encephalopathy, lactic acidosis, and stroke (MELAS) with acanthocytosis [34]

Mitochondrial for MELAS but this case is not proven

Mitochondrial genome for MELAS but this case is not proven

This is a single case. Typically, MELAS is an A3243G mutation. (Adenine is replaced by guanosine at position 3243 in the mitochondrial genome.) This single case report did not have mitochondrial genomic sequencing. Pathology reports showed abnormalities in Betz cells, brainstem neurons, and anterior horn cells. Muscle pathology results are compatible with MELAS.

N/A

Familial acanthocytosis with paroxysmal exertion-induced dyskinesias and epilepsy (FAPED) [35]

Autosomal dominant (not certain; only one family)

 

This is characterized by intermittent attacks of cramps and involuntary movements; attacks are myoclonic and atonic epilepsy. It has been described in one family. MRI showed mild basal ganglia degeneration. Positron emission tomography scanning showed decreased glucose metabolism in the thalamus.

#246700

Anderson disease, now part of chylomicron retention disease (CMRD)

Autosomal recessive

Sar1B gene, 5q31.1 [36]

Severe intestinal fat malabsorption with diarrhea, steatorrhea, hypobetalipoproteinemia, low cholesterol, triglyceride and phospholipid levels, and failure to secrete chylomicrons after a fatty meal. Typically lacks acanthocytes, retinitis pigmentosa, and ataxia. Rare cases may be associated with acanthocytes and some neurologic problems and so may be considered neuroacanthocytosis. A single mention of features of neuroacanthocytosis is found in book chapter [37] and reference to same chapter [38] .

+278000 or 278100

Atypical Wolman disease [39]

Unknown (single case)

Unknown (single case)

In 1970, Eto and Kitagawa described a patient with lipid malabsorption, vomiting, growth failure, adrenal calcification, hypolipoproteinemia, and acanthocytosis and termed it Wolman disease (OMIM #278000) [39] . The patient had hepatosplenomegaly, steatorrhea, abdominal distention, and adrenal calcification that appeared in the first weeks of life, as well as widespread accumulation of cholesterol esters and triglycerides in the internal organs. Typically, Wolman disease is not associated with acanthocytes or neurologic problems. This single case has now been given its own number (OMIM #278100). Whether this case is truly Wolman disease is uncertain.

Stephen A Berman, MD, PhD, MBA Professor of Neurology, University of Central Florida College of Medicine

Stephen A Berman, MD, PhD, MBA is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, Phi Beta Kappa

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Nestor Galvez-Jimenez, MD, MSc, MHA The Pauline M Braathen Endowed Chair in Neurology, Chairman, Department of Neurology, Program Director, Movement Disorders, Department of Neurology, Division of Medicine, Cleveland Clinic Florida

Nestor Galvez-Jimenez, MD, MSc, MHA is a member of the following medical societies: American Academy of Neurology, American College of Physicians, International Parkinson and Movement Disorder Society

Disclosure: Nothing to disclose.

Selim R Benbadis, MD Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, Tampa General Hospital, University of South Florida Morsani College of Medicine

Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, American Medical Association

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Acorda, Livanova, Eisai, Greenwich, Lundbeck, Neuropace, Sunovion, Upsher-Smith.<br/>Serve(d) as a speaker or a member of a speakers bureau for: Livanova, Eisai, Greenwich, Lundbeck, Neuropace, Sunovion.<br/>Received research grant from: Acorda, Livanova, Greenwich, Lundbeck, Sepracor, Sunovion, UCB, Upsher-Smith.

Roberta J Seidman, MD Associate Professor of Clinical Pathology, Stony Brook University; Director of Neuropathology, Department of Pathology, Stony Brook University Medical Center

Roberta J Seidman, MD is a member of the following medical societies: American Academy of Neurology, Suffolk County Society of Pathologists, New York Association of Neuropathologists (The Neuroplex), American Association of Neuropathologists

Disclosure: Nothing to disclose.

Paula K Rauschkolb, DO Assistant Professor of Neurology and Medicine, Geisel School of Medicine at Dartmouth; Consulting Staff Physician, Department of Neurology, Department of Medicine, Section of Hematology/Oncology, Dartmouth-Hitchcock Medical Center

Paula K Rauschkolb, DO is a member of the following medical societies: American Academy of Neurology, American Medical Association, American Society of Clinical Oncology, Society for Neuro-Oncology

Disclosure: Nothing to disclose.

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author Maritza Arroyo-Muñiz, MD, to the development and writing of this article.

Neuroacanthocytosis

Research & References of Neuroacanthocytosis|A&C Accounting And Tax Services
Source